Eupraxia Pharmaceuticals Net Income Over Time
| EPRX Stock | 8.42 0.29 3.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Eupraxia Pharmaceuticals Performance and Eupraxia Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. Projected growth potential of Eupraxia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Eupraxia Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Eupraxia Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eupraxia's accounting equity. The concept of intrinsic value - what Eupraxia Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Eupraxia Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eupraxia Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eupraxia Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eupraxia Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Eupraxia Pharmaceuticals and related stocks such as Mediwound, Nautilus Biotechnology, and NeOnc Technologies Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDWD | (6.2 M) | (6.2 M) | 10.9 M | (15.4 M) | (18.9 M) | (22.1 M) | (18.9 M) | (22.1 M) | (1.1 M) | 5 M | (9.2 M) | (13.6 M) | (19.6 M) | (6.7 M) | (30.2 M) | (27.2 M) | (25.8 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| NTHI | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3 M) | (14.9 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| SLS | (2.4 M) | (11.5 M) | (35 M) | (76.7 M) | (36.6 M) | (63.9 M) | (23.5 M) | (23.8 M) | (27.7 M) | (19.3 M) | (16.8 M) | (20.7 M) | (41.3 M) | (37.3 M) | (30.9 M) | (27.8 M) | (29.2 M) |
| IVA | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.5 M) | (8.8 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (31.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| RNAC | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (25.2 M) | (36.2 M) | (65.3 M) | (65.3 M) | (55.4 M) | (68.9 M) | (25.7 M) | 35.4 M | (219.7 M) | (77.4 M) | (69.7 M) | (73.2 M) |
| GNFT | 2.2 M | (9.7 M) | (5.4 M) | (12.7 M) | (17 M) | (17.1 M) | (33.7 M) | (58.6 M) | (79.5 M) | (65.1 M) | (101.2 M) | 67.3 M | (23.7 M) | (28.9 M) | 1.5 M | 1.4 M | 1.4 M |
| TARA | (8 M) | (8 M) | (8 M) | (7.9 M) | (3.3 M) | (21.4 M) | (28.5 M) | (30 M) | (25.4 M) | (15 M) | (34 M) | (47.3 M) | (66 M) | (40.4 M) | (44.6 M) | (40.1 M) | (42.1 M) |
Eupraxia Pharmaceuticals and related stocks such as Mediwound, Nautilus Biotechnology, and NeOnc Technologies Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Eupraxia Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Eupraxia Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Eupraxia Pharmaceuticals Common | EPRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2067 Cadboro Bay |
| Exchange | NASDAQ Exchange |
null 8.42
Additional Tools for Eupraxia Stock Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.